Selective Endothelin Type A Receptor Inhibition In Cardiac Surgery Subjects With Pre-Existing Cardiovascular Risk Factors: A Dose Confirmation Study.

Trial Profile

Selective Endothelin Type A Receptor Inhibition In Cardiac Surgery Subjects With Pre-Existing Cardiovascular Risk Factors: A Dose Confirmation Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2012

At a glance

  • Drugs Sitaxentan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms FCAD02
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top